

14-Apr-2020

OrganiGram Holdings, Inc. (OGI.CA)

Q2 2020 Earnings Call

CORPORATE PARTICIPANTS

Amy Schwalm

Vice President-Investor Relations, OrganiGram Holdings, Inc.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

Paolo de Luca

Chief Strategy Officer, OrganiGram Holdings, Inc.

OTHER PARTICIPANTS

Tamy Chen

Analyst, BMO Capital Markets (Canada)

Andrew Partheniou

Analyst, Stifel Nicolaus Canada, Inc.

Rupesh Parikh

Analyst, Oppenheimer & Co., Inc.

Graeme Kreindler

Analyst, Eight Capital

Christopher M. Carey

Analyst, BofA Securities, Inc.

John Zamparo

Analyst, CIBC World Markets, Inc.

Matt Bottomley

Analyst, Canaccord Genuity Corp.

Douglas Mieh

Analyst, RBC Capital Markets

David M. Kideckel

Analyst, AltaCorp Capital, Inc.

MANAGEMENT DISCUSSION SECTION

Operator: Good morning. My name is Lisa and I'll be your conference operator today. At this time, I would like to welcome everyone to the Organigram Holdings, Inc.'s Second Quarter 2020 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. We ask that you please limit yourself to one question and one follow-up question. You may re-queue if further questions. As a reminder, this conference call is being recorded and a replay will be available on Organigram's website.

At this time, I would like to introduce Amy Schwalm, Vice President-Investor Relations. Ms. Schwalm, you may begin.

Amy Schwalm

Vice President-Investor Relations, OrganiGram Holdings, Inc.

Thank you, operator. Joining me today are Organigram's Chief Executive Officer, Greg Engel; Chief Financial Officer, Derrick West; and our Chief Strategy Officer, Paolo de Luca. Please bear with us today as we are all doing this call remotely from our homes. Before we begin, I'd like to remind you that today's call will include estimates and other forward-looking information from which our actual results could differ. Please review the cautionary language in today's press release regarding various factors, assumptions and risks that could cause our actual results to differ.

Furthermore, during this call, we will refer to certain non-IFRS financial measures. These measures do not have any standardized meaning under IFRS and our approach in calculating these measures may differ from that of other issuers and so may not be directly comparable. Please see today's earnings report for more information about these measures.

I will now hand the call over to Greg.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Thanks, Amy. Good morning and thank you for joining us today. This morning, we reported results from our second quarter of fiscal 2020 ended February 29, 2020. Before I begin, I would like to welcome Derrick to his first earnings call as our Chief Financial Officer and Paolo as our Chief Strategy Officer. I'll provide some overall remarks on the quarter as well as on current developments, and then Derrick will take you through our financials in more detail.

All three of us will be available to answer questions before we close call by no later than 9:00 AM Eastern Time. First of all stepping back, I've two important messages I want to come through clearly this morning. First, we are pleased with our continued execution in the second quarter and with the demand for our new products in the market today including Rec 2.0 SKUs as well as new core streams being introduced across the country. And secondly, we believe we're well positioned with our plans to manage through these very uncertain times for a number of reasons which I'll go through shortly.

So turning to the quarter, adult-use recreational revenue was up 16% sequentially driven by the launch of our first Rec 2.0 products despite total revenue being down on lower wholesale revenue. The adult-use rec market is our core business and represents the most significant growth opportunity for us. We also continue to introduce new streams after these sold exceptionally well as limited time offers in the past. Limelight, which averages about 20% to 25% THC, was available in Alberta, BC, Quebec, Nova Scotia and New Brunswick in mid to late February and is launched in the remainder of the provinces including Ontario in Q3.

El Dorado, a recent addition to our hybrid category, averages about 18% to 20% THC and had distribution to all provinces in Q2 with the exception of Nova Scotia and BC, both of which are expected to come in Q3. We expect to continue to see wholesale market demand for our indoor grown products over the next couple of quarters. But this is not our primary focus and more of an opportunity for us in the near term. We have continued to diversify our revenue streams.

During the quarter, Rec 1.0 products represented about 52% of net revenue. New Rec 2.0 products including chocolates and vapes represented 13% of net revenue. Wholesale revenue from other large Canadian LPs represented 24% with Canadian medical sales representing 10%, international sales representing 1%.

The company continues to actively seek opportunities to expand its product mix and customer base. The second quarter marked a milestone for us. The launch of our initial Rec 2.0 products, we began shipping Trailblazer Torch vape cartridges on December 17, 2019, and right before the quarter closed, we made our first shipments of Edison vape pens and Edison Bytes, our premium cannabis-infused chocolates. Powered by Feather technology, Edison vape pens are ready-to-use inhalation activated pens that are designed to offer a simple and intuitive user experience. Feather is a cannabis vape pen company currently selling products in Colorado and we have secured exclusivity with them in the Canadian market.

Edison Bytes are premium truffles in both milk and dark chocolate formulations and available as a single chocolate containing 10 milligrams of THC each and a set of two truffles containing 5 milligrams of THC each. PAX ERA cartridges, our third and final vape offering for the premium segment of the market, are expected to launch before the end of calendar Q2 2020. Notably, we've secured listings in all provinces that allow edibles and vapes for our Rec 2.0 products. Along with our license renewal received this month, we also obtained licensing approval for the remainder of Phase 5 of our facility, which serves as a dedicated edibles and derivative product facility. The market continued to see price compression for Rec 1.0 products, but our average net selling price held up well and remained above CAD 5 per gram excluding wholesale.

Our cost of cultivation remained one of the lowest in the industry which better positions us against pricing headwinds. In fact, our cost of cultivation decreased from the previous quarter to CAD 0.53 per gram on a cash basis and to CAD 0.75 per gram all-in. Q2 gross margin before fair value changes to biological assets and inventories sold declined somewhat from Q1 as we launched a number of Rec 2.0 products for the first time. Importantly, we see opportunity to drive improved gross margin as we continue to scale and optimize Rec 2.0 products [ph] impact (00:06:01).

Adjusted EBITDA was negative in Q2 primarily due to a large brand campaign for Edison that ran during the quarter and higher cost related to the launch of Rec 2.0 products. As I've said before, prudent cost management is deeply embedded in our culture at Organigram. We've seen most of our competitors announce executive turnover and/or complex cost restructuring plans while we've been able to stay focused on execution and have not faced these same disruptions.

However, we are all facing even more challenging times today with COVID-19 global pandemic. Our priority is to protect the health and well-being of our employees. It was clear many facility staff are not comfortable coming into work particularly if they weren't able to practice sufficient physical distancing even with the additional measures we put in place. It was no longer possible to continue to operate our facility in a business-as-usual approach. We know we are not alone and other LPs are also experiencing employee absences and reduced operational activity for the same reasons.

As such, we developed a plan intended to help protect the health of our employees and maintain business continuity to service our medical patients and customers. We offer temporary voluntary layoffs to facility staff and those that accepted made up the majority of those temporarily laid off. Lump sum payments equating to approximately two weeks' worth of work have been paid to the affected employees to help bridge the gap to government programs.

In addition, we will absorb the employee pay portion of health, dental and short-term disability premiums for all employees during this difficult time. The impact of these temporary layoffs will result in a one-time charge of approximately CAD 0.6 million. We have maintained an experienced group of employees at the facility with skills flexible enough to work on various production and packaging lines as demand dictates. There were also a select number of administrative and other employees who were temporarily laid off as a result of reduced operations and/or deemed non-essential in the short term.

To be clear, we did not make these changes because we had any employees that tested positive for the virus. [ph] We invariably (00:08:59) made these changes because New Brunswick is any worse off than any other parts of the country. In fact even though New Brunswick is reported to conduct about 10% less testing than the national average to-date, the province has reported to have 78% fewer confirmed cases per capita than the national average. We applaud the actions the government has taken in an effort to contain the virus in New Brunswick.

Prioritizing the health of employees and being proactive in our containment efforts, we believe this puts us in a better position in the medium to long term while still being able to manage our operations in the near term. We continue to closely monitor the evolving situation and prepared to make decisions in the best interest of our employees balanced with the long-term sustainability of our business. We have no current plans to reduce medical production as we intend to continue our service to our patients who have come to rely on our products.

In fact just last week, we expanded our distribution with our first shipment to Shoppers Drug Mart under distribution agreement we previously announced in February. With reduced capacity, we are focusing on the most automated and efficient lines of production and packaging and are able to supplement with finished goods inventory on hand in an effort to meet demand in the short term. A good example is our Edison Bytes chocolate truffles with our automated production and packaging equipment.

Also, we recently started operating a T0 trimming machine since we received licensing approval for the remainder of Phase 5 in mid-March. The T0 does the same work as 12 T4s and requires significantly less manual labor to clean than multiple T4 machines. It also means that we have to deprioritize certain products with lower margins and/or those reliant on more manual processes in this temporary period. Where possible, we also shift our production mix to larger format SKUs as online purchasers tend to prefer those. We are also evaluating new brand of product launches during this time.

We are no longer providing guidance as to the launch timing of our new powdered beverage product and ANKR, our recreational organic dried flower product. Although there has been great interest in our powder beverage from our provincial partners, it is still estimated to comprise a smaller percentage of sales relative to vapes and chocolates. Similarly, despite having ANKR product ready to package, we need to assess priorities in light of a reduced workforce and current consumer demand. Dried flower vape pens and chocolates will be mainstays for the foreseeable future.

Now turning to current demand. We've seen an uptick in March sell-through as well as more orders from provinces have happened. Consumers continue to have access to purchase cannabis across the country with most retail stores remaining open or offering click and collect or curbside pickup. In addition, online sales run by the provincial cannabis bodies and private retailers where applicable are experiencing surges in sales as purchasers adhere to stay-at-home directives. As a company, we're actively monitoring these trends, but still need more time and data to evaluate just how much is due to pantry loading versus a sustained change to purchasing habits.

While it remains to be seen, there is evidence to support cannabis demand is just as inelastic as demand for alcohol. A survey of 1,005 US consumers by MKM Partners found that media, alcohol and cannabis were the categories that showed the highest indications of discretionary spending as a result of the pandemic. There are factors that tend to support increased consumption even in light of an economic downturn. As consumers pare back spending on higher ticket items such as dining out and travel, cannabis is relatively less expensive and still provides the recreational experience. Stay at home and physical distancing directives offer more opportunity to consume cannabis in private settings which is what our own market research indicate is to be expected particularly for edibles.

I would now like to turn to our ability to supply this demand. As we announced last week, we believe we have sufficient inventory levels to supplement reduced harvest plans and enough contingency staff to keep packaging intact to meet anticipated demand in the short term. We also remain comfortable with our current inventory from external suppliers such as vape product hardware and packaging materials have not experienced any significant disruptions to-date. We provide some detail on the breakdown of inventory in Note 7 of our financial statements,

so I'd ask you to please turn to that to review. Our finished good dried flower inventory is largely comprised of higher THC product and our most popular strains.

Further, the majority of upcoming harvests are comprised of strains in higher demand including Limelight and El Dorado. As we have been saying, we contribute this to the benefit of our early views on retail sell-through allowing us to shift our production mix starting last year.

With that, I will now turn the call over to Derrick.

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

Thank you, Greg. Since I joined early last month, it has certainly been an eventful time in the industry and globally to say the least. In any event, I'm very happy to be here and look forward to meeting many of you on the call virtually and eventually in person when it is safe to do so. I've been getting up to speed quickly and it has helped to have had the vantage point from previously being on the company's board and chair of the audit committee.

I will begin with some comments on our financial position. As at quarter end, our remaining estimated capital spend on Phase 5 was CAD 11 million, largely related to the installation of certain equipment in edibles and extraction area. We expect to spend at a slower pace to bounce near-term priorities with respect to COVID-19. Our remaining estimated spend on Phase 4 is quite marginal at about CAD 2 million. We are pleased to see our capital expansion nearing completion. We believe we have built an impressive indoor facility capable of producing high quality, low cost flower as well as premium chocolates and other derivative products.

We ended the quarter with CAD 41 million in cash in short-term investments. As of today, there is CAD 30 million undrawn on our term loan and a CAD 25 million revolver available to be drawn against specified receivables. As at quarter end, working capital declined to CAD 97 million from CAD 152 million at fiscal 2019 year-end. This was largely due to an IFRS requirement to classify the long-term portion of the term loan to current liabilities because we were in violation of our fixed charge coverage ratio covenants.

We obtained a waiver from our lenders that waives compliance until May 30, 2020. We are currently negotiating an amendment to the credit facility agreement in an effort to provide flexibility as a result of the impact of COVID-19. We reported approximately CAD 85 million in current and long-term debt as at quarter end, which primarily represents the carrying value of the term loan in our credit facility with BMO and a syndicate of lenders. In December of 2019, we announced an aftermarket offering or ATM program which allowed us to issue CAD 55 million or its US dollar equivalent of common shares from treasury. We issued approximately 16.2 million common shares pursuant to the ATM program in Q2 for gross proceeds of approximately CAD 55 million at a weighted average price of CAD 3.39 per common share. Although the price per share I just quoted was in Canadian dollars, approximately two-thirds of the shares issued were on the Nasdaq exchange with the remaining on the TSX.

Net proceeds were CAD 52.9 million after agents' commissions, regulatory and legal and professional fees. We have used and intend to continue to use the net proceeds to fund capital projects for general corporate purposes and to repay indebtedness. The ATM program was completed before quarter end.

Moving to our quarterly results. Q2 net revenue of CAD 23.2 million compared to CAD 26.9 million prior year quarter. The decline from 2019 was largely due to a decrease in adult use recreational sales volumes as a result of the timing of the large pipeline fill orders in Q2 2019, which was to fulfill supply shortages in Alberta and Ontario, following the legalization of adult use recreational cannabis, a lower average net selling price from

increased competition, a provision for returns and price adjustments largely related to cannabis oil, which has seen less than anticipated demand in the industry and other slow-moving product. This decline was partially offset by the launch of our initial Rec 2.0 products and continued wholesale revenue in Q2 2020.

Q2 2020 net revenue of CAD 23.2 million compared to Q1 2020 net revenue of CAD 25.2 million. Adult use recreational sales were up approximately CAD 2.1 million or 16% offset by a decrease in wholesale revenue. Q2 2020 net revenue of CAD 23.2 million was largely comprised of CAD 15 million in sales to the adult use recreation market, CAD 2.4 million sales to the medical market and CAD 5.6 million and CAD 0.2 million in wholesale and international sales, respectively. This compared to Q1 2020 net revenue of CAD 25.2 million, which was largely comprised of CAD 12.9 million in sales to adult use recreation market, CAD 2.7 million in sales to the medical market and CAD 9.2 million and CAD 0.3 million in wholesale and international sales, respectively.

As Greg mentioned, Q2 cash and all-in cost of cultivation were CAD 0.53 and CAD 0.75 per gram, respectively, and decreased from CAD 0.61 and CAD 0.87 per gram to Q1 2020 as more economies of scale were realized with increased cultivation capacity and as our yield per plant increased from 150 grams in Q1 to a 155 grams in Q2 2020.

Q2 2020 cost of sales of CAD 15.8 million compared to Q2 2019 cost of sales of CAD 10.8 million. Higher cost of sales in Q2 of 2020 was primarily due to more staffing for increased cultivation and post-harvest capacity without the benefit of full economies of scale. Inventory provisions and write-offs primarily related to legacy packaging and thirdly higher costs associated with the launch of Rec 2.0 products as the company scales and optimizes production and packaging.

Q2 gross margin before fair value changes to biological assets and inventory sold was CAD 7.4 million or 32% of net revenue. As we have said in the past, we focus on gross margin before fair value change to biological assets and inventories as one of the key measures to assume underlying performance and generally find this to be what the investment community tends to track. The Q2 IFRS gross margin was CAD 11.3 million, largely due to a net noncash fair value gain on biological assets and inventories sold of CAD 3.9 million versus a net noncash fair value loss of CAD 8.1 million in Q2 2019.

Q2 2020's SG&A, excluding share-based compensation, was CAD 14 million compared to CAD 5.7 million in Q2 2019. As the company increased staffing and sales and marketing efforts, including a significant brand marketing campaign and higher costs related to the launch of our new Rec 2.0 products. We reported negative adjusted EBITDA of CAD 1.1 million in Q2 versus positive adjusted EBITDA in Q1 due to the combination of higher cost of sales and higher SG&A as just described.

Our Q2 net loss was CAD 6.8 million or CAD 0.041 per share on a diluted basis compared to our Q2 2019 net loss of CAD 6.4 million or CAD 0.049 per share, largely due to higher SG&A in Q2 2020.

I will now turn the call back to Greg for closing remarks.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Thanks, Derrick.

To wrap-up our formal remarks, I'd like to summarize why we believe we're well positioned during this temporary period and beyond. First of all, we believe we've developed brand loyalty and a strong demand for our Rec 2.0 products, and we are rolling out new higher THC popular strains across the country. Secondly, we've forged

excellent partnerships and have strong relationships with suppliers, regulators and our provincial and private retail customers.

Third, we maintain a lean cost structure and a relentless focus on prudent discretionary spending. Fourth, we've further strengthened our executive team with the addition of another experienced finance executive and a Chief Strategy Officer, who is intimately familiar with the business. Fifth, we can supplement reduced production capacity with existing inventory as well as leverage our investments in automation to meet demand in the short term. And lastly, we remain committed to focusing on disciplined capital allocation to generate sustainable value for our shareholders.

I'd like to expressly thank the regulators as well as government authorities for including cannabis in the stimulus packages and subsidies in this challenging period. I would also like to thank our customers, patients and investors for their support and last, but not least, the entire Organigram team and our Board of Directors.

With that concludes my formal remarks. Operator, if you could go ahead and open up the line for questions.

QUESTION AND ANSWER SECTION

Operator: Thank you [Operator Instructions] And our first question comes from the line of Tamy Chen from BMO Capital Markets. Your line is open.

Tamy Chen

Analyst, BMO Capital Markets (Canada)

Q

Yeah. Thanks. First question is just wanted to understand is it, at this point, your intention to rehire back the temporary laid off workers after the COVID-19 developments go past us? Or do you intend to wait and see how quickly, for example, stores open in Ontario before bringing back those workers?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yes. It's Greg here. Tamy, that's a good question. So certainly in the intent and the way we structured this is a temporary layoff. So this was structured in a manner that we can bring in plan to bring employees back. But I think the timeframe and the cadence of how we bring employees back is going to be dependent on kind of the growth of the market back in place. So it is our intention to bring them back and that's why we've structured it this way.

Tamy Chen

Analyst, BMO Capital Markets (Canada)

Q

Okay. Thanks. And my second question is on – so I noticed your Rec 1.0 sales were flat to slightly down sequentially. But I believe, in Ontario, the provinces I think almost doubled their store count over the sort of period and into March. So I would have thought you would have experienced some self-selling during this period and increased your Rec 1.0 sales sequentially. So just any color there would be helpful. Thank you.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Sure. In Q2, we were still drawing down on inventory that we have placed in Ontario in Q1, and as well as a move to kind of the more high velocity strains as we said Limelight and Eldorado and ensuring that we moved inventory

there, so it was a bit of a combination of both. So we did have sufficient inventory. So certainly for the majority of Q2, Ontario revenue was still ticking through inventory from Q1.

Tamy Chen

Analyst, BMO Capital Markets (Canada)

Got it. Thank you.

Q

Operator: Our next question comes from the line of Andrew Partheniou from Stifel GMP. Your line is open.

Andrew Partheniou

Analyst, Stifel Nicolaus Canada, Inc.

Hi. Thanks for taking my questions. I'm just curious how's your cost profile now changed with the workforce reduction and especially also the licensing of Phase 5?

Q

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Yeah. So I'll start off and maybe ask Derrick to add some color. I mean, so we've had a workforce reduction. I think, we're still assessing our capabilities and exploring how – what impact that's going to have as we've indicated both in our press release related to the temporary layoffs as well as the current information in this press release is, we are moving as much as possible to automated lines and system. And so to make a comment, I think, we can't give guidance yet in terms of what impact that will have, but it is a shift to as much automated systems and higher SKU, higher large format SKUs as well where possible on flower.

A

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

Yeah, Derrick here. I would just add that our largest cost is our labor cost and so we will achieve, obviously, the savings from the layoffs in terms of our labor costs, and we – obviously, that will reduce our total production announced, but we do believe that we're going to get some balance as it relates to the SKUs that we'll be focusing on, the product lines that we're focusing on, but again, we're not in a position, at this time, to provide any future guidance on exact amounts.

A

Andrew Partheniou

Analyst, Stifel Nicolaus Canada, Inc.

Okay. Thanks. And why – are you able to provide maybe some kind of a distribution between savings on SG&A versus COGS?

Q

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

We're not at this point. So we just, again, we're still working through kind of as we – we've only now been running two weeks with kind of the reduced structure, so we're not able to give guidance at this point.

A

Andrew Partheniou

Analyst, Stifel Nicolaus Canada, Inc.

Okay. Thanks.

Q

Operator: Our next question comes from the line of Rupesh Parikh from Oppenheimer. Your line is open.

Rupesh Parikh

Analyst, Oppenheimer & Co., Inc.

Q

Good morning, thanks for taking my questions. So I wanted to ask a little bit more about gross margins. So, as we look out to the balance of the year, how should we think about the gross margin? Should we expect sequential improvement versus what we saw in Q2?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Maybe, I'll turn that over to Derrick to answer.

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

A

Yeah. Just I don't want to comment too much about future margins, but I can comment that, for the margin that we have, the adjusted gross margin of 32%, that was after we did allowances for packaging and material on certain product lines and the impact of that was CAD 1.3 million or 5.5%. So while there's always going to be these types of adjustments, it would probably be a larger than normal adjustment to happen in one quarter. And without that adjustment, the margin would have been, on a pro forma basis, 37.5%. But I'm not going to, at this point, provide any kind of future guidance in terms of our margins.

Rupesh Parikh

Analyst, Oppenheimer & Co., Inc.

Q

Great. And then, I guess, one follow-up question just on pricing. So I know there's some pricing pressures within the marketplace right now. Just wanted a bit more color in terms of what you guys are seeing and if there's any forward commentary in terms of how you're thinking about pricing pressure is going forward?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah. Maybe – so, thanks, Rupesh, it's Greg Engel here again. So I think where we've seen, I mean, we've still maintained an average selling price of the product that we're selling into the direct market about CAD 5, and I think we are seeing pricing pressures, and we've always made the assumption that the pricing pressures would come because of large SKUs that were coming into market, and we are seeing that.

And I think it's important to understand that some of this competition is being driven out of short-term needs from companies who have had to move product. And when you look at the price they're selling at versus what their production costs are, I'm not sure they're actually even making money on some of these products, so not a sustainable pricing strategy beyond the near term. I think where we have an advantage, we are looking at larger SKU formats is that our average costs of cultivation and all-in costs are quite low compared to many of our competitors. So we've got the best of both worlds. I guess, when you look at it, we're producing high-quality product as well as at a very low cost. So I think that's where we're seeing most of the pricing pressures really on the large SKU formats on the lower end.

Rupesh Parikh

Analyst, Oppenheimer & Co., Inc.

Q

Great. Thank you.

Operator: Our next question comes from the line of Graeme Kreindler from Eight Capital. Your line is open.

Graeme Kreindler

Analyst, Eight Capital

Q

Hi. Good morning and thank you for taking my questions here. I was wondering if you could comment on what the ordering patterns from the provinces are looking like given the current environment that we're in? I know, historically, we went from larger ordering patterns to smaller more frequent orders. Now that we're in a situation where it looks like there's spikes in demand, followed by commensurate sort of decline in demand, I'm just wondering if the ordering pattern behavior from the provinces has changed at all and how you're responding to that? Thanks.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah, I think certainly we saw as kind of stay-at-home orders started to come into play, so a pretty significant shift in kind of demand and provincial retailers and private retailers were looking to stock up in advance at where with the demand they were seeing. I think one of the challenges that we have seen for those with that operate large warehouses like Ontario and Alberta is that they have staffing reductions within those facilities as well. So even though they wanted significant amounts of products, they ended up having to take them over a more pushed out period of time.

So, while the demand – there was a sudden kind of increase in demand, and we still see very strong online sales, and we are still seeing strong cannabis sales. It has been pushed out even more so that demand was there, but they are getting the shipments in with kind of spaced out a little more. So in many ways, it's actually easier to manage for companies like ourselves and others to get sequential product, and we continue to see strong demand especially for, as I commented, our leading strains and our Rec 2.0 products.

Graeme Kreindler

Analyst, Eight Capital

Q

Okay, thank you. And as a follow-up, with respect to the wholesale market, I was wondering if there's been any increase in demand there given I would assume there's a number of operators who are working on a reduced staffing level, which could impact their harvest and given looking at some of the breakdown of the inventory that's disclosed on the balance sheet there, is there a potential for any more opportunistic sales moving forward on the wholesale channel?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

So, I guess, the comment I would give on that, Graeme, is we've had additional in-bounds, we've expanded who we sell to. So, I mean, we do have one additional company that we have been selling wholesale to than previous quarter. And we've had additional in-bounds as well. So the answer is yes, there's demand there. And I think, again, having that inventory and having the quality inventory which we've commented in the past is a big differentiator. But I can't necessarily until you've completed an agreement and until you've made a sale, there's in-bound interest, but I can't say more than that.

Graeme Kreindler

Analyst, Eight Capital

Q

Okay. I appreciate the color. Thank you.

Operator: Our next question comes from the line of Chris Carey from Bank of America. Your line is open.

Christopher M. Carey

Analyst, BofA Securities, Inc.

Hi. Good morning.

Q

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Hi, Chris.

A

Christopher M. Carey

Analyst, BofA Securities, Inc.

So, I guess, maybe just one question on the cash flow. Then I have a follow-up, but I guess this quarter, cash burn represents about a quarter of the cash on hand and then, I guess, when you add the term loan in the credit facility, which is another CAD 55 million, you have about two quarters of liquidity relative to cash burn this quarter. So I wonder if you can help me just understand the cadence of cash flow expectations from here. And I appreciate that CapEx is likely to step down. Perhaps, you can provide some visibility there and maybe have operating cash flow. So just a big picture there, how this cash use for cash sources likely to move over the next several quarters?

Q

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

Yeah, Derrick here.

A

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Yeah, go ahead, Derrick. I was going to refer to you, please.

A

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

Okay. Yeah, for the first six months, a large amount of the reduction in our cash position has related to the CapEx spend. Yes, there is a working capital or cash from operations deficiency of CAD 25 million to be in the February as a consequence of our working capital sale that did occur mostly the consequence of [indiscernible] (00:33:17). But I would indicate that, as at the end of the second quarter, our cash was at CAD 41 million. We are not required to continue on an aggressive CapEx program to complete foresee we're talking about CAD 2 million more that could be spent over the next period and CAD 11 million as it relates to [indiscernible] (00:33:48) bring professionals in to assist to [indiscernible] (33:52) certified because of the COVID-19 impact and social distancing.

A

So we have a lot spend going forward of approximately CAD 13 million and that CAD 13 million spend is going to be done and it's going to be slowed down dramatically from what we spent in the past. So when you consider that and the fact that we have CAD 41 million in cash at the end of the second quarter that we do have CAD 25 million remaining on the term loan for the credit facility, and while there's no guarantee that will be successful in amending the credit facility, we do believe that we will be [indiscernible] (00:34:30) this time.

So the combination of that does provide sufficient liquidity and cash that will take us past – that will take us into the future, and we always have – whenever the company's been in a situation where it wanted to access other sources of capital, it's always done so when it's required, but we don't believe it's required at this time.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah. Maybe to just clarify, Derrick, you were referring to what we have remaining on the long-term debt, so we have CAD 25 million as revolver and we have CAD 30 million on the debt [indiscernible] (00:35:12) remaining, so.

Christopher M. Carey

Analyst, BofA Securities, Inc.

Q

Right. Right. Okay. All right. That's helpful. And then I guess as a follow-up, it just feels and I think Tamy mentioned it as well. It just feels like the adult-use business after kind of storming out of the gates last year and I fully appreciate that that was a pipeline fill, but it does feel like it just has struggled to really regain that position in the market that it had before and I appreciate the comments on provinces like Ontario are starting to work down the inventory that they have. But it doesn't sound to me from the answer to the prior question that you're at the point where your inventory levels in the channel have now reached kind of a clean level and then you can start to refill at an area where maybe you start to retake some market share. And so I wonder it's a high level question if you think it's an unfair assessment that the business has stalled a little bit and maybe how you might see things starting to develop over the next couple of quarters. And then if I could just sneak one in here. I mean do you think that the industry can even grow in your upcoming quarter with so many stores going click and collect or is the click and collect and online demand is such that the category, the industry at large can still grow. So thanks so much for those.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah. So maybe I'll take part of that question, Chris, and then I'll turn things over to Paulo. So I think when first of all to answer the second part of your question, I mean there's significant – the majority of stores across the country with this and if you include Ontario are still open. [ph] PI (00:36:56) only have four stores, they closed their stores. They're doing click and collect – or sorry, online. And then in Ontario, they made a decision to close the stores as you're aware of and then within a couple of days reverted back to click and collect and they are going to have local order. So the demand is there and I think the comment I made earlier which is interesting is that again consumers and the population in general has limited opportunities for spend.

We've seen and we look at, I mentioned some of the survey data from earlier, we've seen in the past for example if you go back, there was a major ice storm in Canada back in the late 1990s on the whole East Coast and in Québec. Alcohol sales for the month of February where the power was out for three weeks was the highest it had been for the last couple of years at that point. So with limited available use for spending kind of their entertainment dollars, I think certainly demand for cannabis continues to be strong.

Back to your first question, I think when you look at – I think, look, there was a lot of excitement to Rec 2.0 products and that has brought an expanded consumer base into the legal market. I think one of the challenges has still been on the Rec 2.0 products is product availability as we saw when Rec 1.0 launched and secondly is that the provinces in some cases didn't expect the demand to be as high as possible, so they were – they wanted to keep their inventory levels down and then make decisions on reorders. For one of the large provinces for example, we had reorders happened on our Trailblazer vape pens before that even hit the store shelves because

the fill demand from the stores was very, very high. So I think there has been a lot of excitement and brought new consumers in through the Rec 2.0 products. And maybe I will let Paolo add a little bit, I know this is one of the areas he focuses on.

Paolo de Luca

Chief Strategy Officer, OrganiGram Holdings, Inc.

Hey can you guys hear me okay?

A

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

Yes.

A

Paolo de Luca

Chief Strategy Officer, OrganiGram Holdings, Inc.

Perfect. Hey, Chris. So, look, this quarter that we're in is obviously kind of a once in a lifetime quarter in terms of the uncertainty around COVID and we're just learning right now what's happening in terms of consumer behavior both kind of in the pantry loading that we saw last month when people were worried that the stores would close down and subsequently that hasn't been the case for the most part as Greg alluded to and we do have a little bit of a different world right now where you have click and collect in the province for example like Ontario online [ph] already (00:39:43). So we're monitoring that. We're trying to see what's happening there, but we do see some positive anecdotes where for example people are actually shifting to the legal market now because they don't want to interact with their black market dealer, they don't want to meet the person physically, they don't want to change cash which is a concern for people in terms of the virus spreading. So, that's all to be determined and we know we're going to obviously respond in whichever way we think is best to take advantage of the opportunity that may present itself as a result of that.

A

And in terms of just the logistics of the entire market, we are dependent obviously on the consumer behavior, we're dependent on the ability of the provinces to have the logistics in place and not to have disruptions there in terms of their ability to stock at the distribution centers and so forth. Our view at this quarter is difficult to forecast to be – there could be opportunities for us to do well in certain products and take advantage of opportunities, but we just don't know. It's a very unknown quarter. Where we are focused is longer term on our core strength, which as to become a leader in the chocolate segment and to become a leader obviously with some of our new strains like Limelight and El Dorado, which we've mentioned in the past. I think one of the things to look at in the way that the Rec market has developed over the last, call it, six to nine months, we've seen some of our competitors adopt pretty aggressive pricing strategies to move to larger SKU formats. There's nothing proprietary in what they've done in those segments and in fact we are actually in the best position to take advantage of some of those opportunities.

So if we need to toggle our SKU mix and our product offering to participate in that market, we can do so and we're going to do so cautiously and with a lot of thought. But right now, we're – really our focus this quarter on our best performing products and to use our reduced work force in a manner which can drive the most revenue for the least amount of cost.

Christopher M. Carey

Analyst, BofA Securities, Inc.

Okay. Thanks so much.

Q

Operator: Our next question comes from the line of John Zamparo from CIBC. Your line is open.

John Zamparo

Analyst, CIBC World Markets, Inc.

Q

Thanks. Good morning. I want to go back to the questions about sell-through. Greg, maybe you could talk about your market share in the quarter versus the prior quarter particularly in larger provinces. Were there any notable changes among your different categories and [indiscernible] (00:42:31) Rec 2.0 products versus Rec 1.0?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

So I guess we don't typically share market share information in part because some of the agreements with the provinces prohibit you from doing that, so some of the data you see out there is actually a bit of a breach of some of the agreements. I mean there is public information on a few of them and I know many of allies are kind of accessing, intermediaries accessing some to publish, but I think two comments I would make is I think certainly with our Rec 2.0 products launch, our vape portfolio starting out with Trailblazer and then adding in the Feather pen has had a strong position. There's one company certainly that went with a price strategy on vapes and they have a very – they would – in Ontario for example, they would be the leader. And one of the other key comments I would make on vapes is we've seen challenges from other companies, right, with leakage and with product returns and that's not an issue we've faced and I think it's important to contemplate that that we've really focused on very high quality suppliers. We've vetted our suppliers, we know that there is not performance issues or leakage issues or having a lead chain and those are critical for us.

On our chocolates, still early days. We only shipped at the end of the quarter our first couple of shipments and in this quarter we've been getting significantly more product out, but I mean there were provinces like Ontario that went a few weeks without our chocolates available. So demand has been there and I think we are seeing a shift as we alluded to and we've allowed our production capability and capacity, we've really shifted our production to our core strains and it was one of the advantages of being a leader last year kind of in the first couple of quarters as we got information about what those core strains are. So our Rio Bravo and La Strada are strong strains for us, but then subsequently we did these one-time offers with Limelight and El Dorado, and we've had really strong response to them. So we've got additional strains that we're going to do one-time offers with as well that are high THC, we believe would be somewhat unique in the market and again the ability to shift again to those products I think is going to continue to provide assistance for us.

John Zamparo

Analyst, CIBC World Markets, Inc.

Q

Okay, that's helpful, thanks. Particularly on the LTOs it seems like that's kind of an untapped part of this market. My follow-up is going back to the balance sheet and cash burn. What do you expect in terms of investments in working capital over the next couple of quarters and generally maybe if we're fast forwarding to next 12 months, what do you view as a normalized maintenance CapEx number?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah, and first, I mean, it's important to kind of maybe answer the first part of it like from a cash flow perspective, we ended the quarter with CAD 41 million. As Derrick outlined earlier, we have limited CapEx remaining to spend and the CAD 2 million on Phase 4C to get it up to fully functional. Not all of the [indiscernible] (00:45:37) operating, but [indiscernible] (00:45:38) occupying a space and then CAD 11 million on Phase 5 which, as noted,

the spend on that will be delayed because of some of the OEMs and working with them to get the kind of equipment certified to be operating it.

So we've got – we're really at the end of our CapEx spend, which is one of the most important things. So I think it's – we feel we have a strong balance sheet at this point in the market relative to [ph] peers is personally (46:02) with having CAD 30 million of undrawn debt capacity with BMO and the syndicate, I mean, there's still no guarantee we can draw that CAD 30 million, but we're certainly working closely with them to be able to do that. But, Derrick, I don't know if you want to add any commentary.

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

A

Yeah. Thanks, Greg. I just want to add specifically as it relates to the working capital. Even in our receivables, we have government HST refunds from the prior CapEx spend that we've already done that's being realized during the third quarter. And also with working capital, our inventory in bio asset are already fairly significant on our balance sheet and we would not – where we have done the reduction to our workforce and we are emphasizing the focus on moving the inventory that's there and producing near-term saleable product. We are not anticipating there to be a cash strain as it relates to further investment into our working capital just as a general comment based upon the reduction to the staff and production levels combined with some of the near-term realization on the working capital.

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

And, John, maybe just to add to the earlier question, part of your question about maintenance CapEx, so we don't have a general rule of thumb because this is primarily a new facility that's been really built over the last couple of years. We expect it to be low-single-digit percentages against the total CapEx, right? The majority of the equipment is new and other than kind of standard maintenance, I mean, we're not in replacement mode. I think even on our irrigation systems in the last two years, we've had to replace one pump and we have redundancies ever. So, again, I think just based on the age of it, you typically might see maintenance CapEx that's in the 4% to 5% [indiscernible] (00:48:06) significantly less than that based on what we're seeing today than based on the age of the equipment.

One thing I didn't comment on earlier and I think was in the prepared remarks that we made, but we have not tapped into any government opportunities and I'd say one of the things that now that with wage subsidies and that being offered and the cannabis industry being included in that, and that was a big win for our association and I know Cameron Bishop, who is our VP of Government Relations, worked really closely with government on that. I think there's also opportunities for us and for the cannabis industry both federally and even provincially to look for some assistance during this period if need, and then I think that's kind of being taken into consideration as well. I mean, there are significant funds available and I think there is definitely an opportunity to access some of those.

John Zamparo

Analyst, CIBC World Markets, Inc.

Q

Okay. Thank you very much.

Operator: Our next question comes from the line of Matt Bottomley from Canaccord Genuity. Your line is open.

Matt Bottomley

Analyst, Canaccord Genuity Corp.

Q

Yeah. Good morning, everyone. Just maybe if you could provide just a little more color on the nature of the fixed charge covenant and is the plan right now just to negotiate with the lender or is there anything that's remedial in the interim that can be done independently?

Derrick W. West

Chief Financial Officer, OrganiGram Holdings, Inc.

A

Yeah, Derrick here. It's just standard cash flow covenant in the sense that you get a certain amount of EBITDA to cover the future debt service on the term loan – on the [ph] CAD 85 million (00:49:41) and we did not meet our Q2 covenant just looking at the trailing 12 month as a consequence of the EBITDA metric not achieving the standard that had been set. There were reasons for that as we've already outlined in our presentation of the information during the call. That would indicate that we've already been – have been in discussions with the lender and since it came to our attention that this was going to be an issue for our Q2 filing, and they very quickly moved forward and obtained the approval of all the lenders and simply get – to provide the covenant waiver and [indiscernible] (00:50:29) us in a very timely way, and that was part of our disclosures.

Going forward, we're still midway through on these negotiations. They provided the forgiveness which until we file our Q3 – until our Q3 balance sheet, so until the May 31 period, and as mentioned, we're in discussions with them now, and while I cannot provide any guarantees based on our working assumption, we don't believe this would be an issue based on those discussions we've had with them to-date.

Matt Bottomley

Analyst, Canaccord Genuity Corp.

Q

Great, that's helpful, and there's been a lot of good color on this call as well with respect to some of the assumptions and inputs here on various parts of your income statement. The follow-up I had is more on the SG&A part. So I know you touched on this briefly already, but just with respect to paring back not only your operational planting and et cetera with your existing facility, but also with some of the pare back as it relates to COVID, what's the best way for us to look at that SG&A line? Obviously, there was a ramp-up this quarter in relation to the launch of Rec 2.0 and all the things you've been doing with your vape pens, et cetera. Maybe the next six months, what's the best way to look at this from a volatility standpoint given that it seems your existing operations now are right around that breakeven on adjusted EBITDA? So, just looking forward, what might make it plus or minus on that breakeven in the next couple of quarters with respect to your SG&A plan?

Gregory Engel

Chief Executive Officer & Director, OrganiGram Holdings, Inc.

A

Yeah. I guess, I alluded to this earlier, Matt, is that it's still early and challenging to give a prediction. I mean, yes, we've had super reduction in our workforce, and certainly there's savings associated with that. It does impact our operational efficiency, which is why we move to the most automated systems and lines and focused on those as a way to best utilize the staff and personnel we have. And I think that is a way for us to optimize both the inventory we already have in existence and then going forward continue to get our products that give us really the greatest return for the amount of labor hours that we have available, and that's how we're mapping it, but as I said earlier, we're only a couple of weeks into this adaptive workforce. I think the one thing we are planning again is because, again, as I commented, we have flexibility based on our production cost is to bring a larger SKU product into the marketplace, and that's been in the plan for a significant amount of time and would have done on the market already had we not hit some of the challenges around COVID-19.

But so, I guess, I've not fully answered your question here because it's very challenging for us to predict. I mean, in many ways, we've taken savings and we've also looked at where our spends are relative to, for example,

marketing programs and we're focusing very much more on kind of digital programs that's online increases and less on some of the other programs we've done historically. So it wasn't just temporary layoffs for health and safety. We also in conjunction with outlook that our production output and what we could actually get up to market, although we do have significant inventory, so.

Matt Bottomley*Analyst, Canaccord Genuity Corp.*

Q

Great. Very helpful. Thank you.

Operator: And our next question comes from the line of Doug Miehm from RBC Capital Markets. Your line is open.

Douglas Miehm*Analyst, RBC Capital Markets*

Q

Yeah, good morning.

Gregory Engel*Chief Executive Officer & Director, OrganiGram Holdings, Inc.*

A

Good morning.

Douglas Miehm*Analyst, RBC Capital Markets*

Q

I just wanted to follow up – it's – yeah, hi – with respect to something you just said a minute or two ago and that is there's no guarantee that we can draw down on the CAD 30 million. Did I hear that correctly?

Derrick W. West*Chief Financial Officer, OrganiGram Holdings, Inc.*

A

Well, there's no guarantee because it's a future event. I'm just stating a factual comment. We are in discussions with them, however. We have had very positive discussions with our lender group as led by BMO and they responded very quickly when we – to provide the way having a waiver letter when we had asked for it and they have indicated the willingness to hear from us on what the renegotiated kind of facility would look like. And clearly as we do this renegotiation, we're going to bear in mind what we believe the EBITDA would be on a go forward basis based upon the COVID-19 impact to our business, to the industry and [indiscernible] (00:55:04) factored in. But I just indicating the obvious that until we've done the renegotiation, I cannot guarantee it, but it's reasonable for us to assume that there's not going to be an issue based on all the indications they've provided to us.

Douglas Miehm*Analyst, RBC Capital Markets*

Q

Okay, perfect. And then when you think about the amount of product that you harvested in this latest quarter at almost 14,000 kilos, I believe you sold about 4,000 kilos of that – just over 4,000 kilos. Is the remainder going for extraction and maybe you could tell us what your extraction, not capabilities, but the deals you have with your partners, are those fixed in stone, do you have to continue to extract a large part of what you're harvesting and what could be the impact of costs there?

Gregory Engel*Chief Executive Officer & Director, OrganiGram Holdings, Inc.*

A

Yeah, so, it's a good question, Doug. Greg here. So our agreement with Valens, who is our contract extraction facility, doesn't have any minimums or requirements, so we have used them and have plans to continue to use them in the future fore hemp. But at some point in the future, we will move all of our extraction in-house when the Phase 5 extraction is fully operational and certified. For the time being, we've got a month's worth of – many months' worth of extract concentrate built up. So we're simply just storing the extractable material before we – and we don't need to send it to Valens because it certainly will be more cost effective to extract it in-house. But so to answer the question, I can't give you an exact number on the inventory that we had available at the end of quarter in terms of what will go, but I mean part of what supported our decision-making around doing temporary layoffs for health and safety reasons was we knew we had sufficient dried flower inventory that we could package and get out into the market and we could reduce kind of our cultivation footprint temporarily because we had that inventory and a lot of that is in high THC and high volume demand strains, Limelight and Rio Bravo and El Dorado and La Strada. So we're in a good position in terms of converting a significant portion or parts of that inventory into a sellable product.

Douglas Mieh*Analyst, RBC Capital Markets*

Q

Okay. Perfect. Thanks very much.

Operator: And we have time for one more question today from the line of David Kideckel from AltaCorp Capital. Please limit to one question. Your line is open.

David M. Kideckel*Analyst, AltaCorp Capital, Inc.*

Q

Hi. Good morning, everybody. Congratulations on the quarter and thanks for taking my question. I just wanted to circle back to one of the points that Graeme made regarding wholesale revenue. Just not even necessarily specific to Organigram, but industry as a whole, I'm just wondering given your remarks, Greg, about consumer loyalty and brand [indiscernible] (00:58:09) and how they are loyal to Organigram to your products in particular, what are your thoughts about different LPs selling to different LPs through the wholesale revenue metric and that the consumer is actually purchasing a product from Organigram, but it's actually coming from a different LP or vice versa. How relevant do you think that is for the general brand and then consumer loyalty across the board?

Gregory Engel*Chief Executive Officer & Director, Organigram Holdings, Inc.*

A

Yeah. Thanks for the question, David. So I think when we look back and we had not historically before Q1 sold product wholesale and we looked at it very opportunistically. We started to get information back in Q2 of last year regarding which of our strains were in higher demand and which ones weren't. But as you know, it takes many, many months to change your production cycle. So we ended up still having production as some of the lower selling SKUs, right, in terms of those flowers and what was available. So we had been getting inbounds from companies that were not satisfied with the product that was available for a wholesale out in the market. So we made a decision to take those products, sell them to another LP, and as to the couple of the comments that were made earlier about – that Matt made as well about kind of one-time offers. We do see that still because there's consumers the same way that if people – if you're a wine drinker or if you're a beer drinker, there's your kind of wines that you buy consistently, but everybody will try different ones, and I think in the cannabis space, there is a of kind of interest and demand in one-time or what's new.

So it's a combination of brand loyalty, but also testing what's new, so there have been some opportunities where companies can take product that was not in high demand under our brand, they've taken it and put it out and it

comes out as a new product under their brand and I think that's where some of those products have been used and that is why as I said earlier our plan to kind of introduce new genetics, cycle them through under one-time offer as to see what the demand and response is and if it's really strong like on our Limelight to increase it into and move it into our core offering. So that's how wholesale really has been structured and government is that it's going to other LPs and they're putting their own brand, but it goes in as kind of a bit of a new product, so.

Operator: And ladies and gentlemen, this will conclude today's call. We thank you for your participation. You may now disconnect.

Disclaimer

The information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error-free statement or summary of the available data. As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. You must evaluate, and bear all risks associated with, the use of any information provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. This information is not intended to be used as the primary basis of investment decisions. It should not be construed as advice designed to meet the particular investment needs of any investor. This report is published solely for information purposes, and is not to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Any information expressed herein on this date is subject to change without notice. Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet CallStreet, LLC. FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securities discussed herein.

THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS," AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.

The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020 CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. All other trademarks mentioned are trademarks of their respective companies. All rights reserved.